title: Antifibrotic effect of combined treatment with neuroleptic drug and immobilized hyaluronidase in pulmonary fibrosis.
abstract: Using the model of lung fibrosis induced by intratracheal administration of bleomycin we studied anti-fibrotic activity of combined treatment with neuroleptic haloperidol and hyaluronidase immobilized on polyethylene oxide using electron-beam synthesis. It was shown that successive administration of immobilized hyaluronidase and the neuroleptic drug inhibits deposition of collagen fibers in the bleomycin-treated lungs. Combined treatment with the test compounds reduced swelling of the alveolar epithelium, exudation and infiltration of the alveolar interstitium and alveolar passages by inflammatory cells, and desquamation of alveolocytes into alveolar lumen, so that the alveolar-capillary membrane function was preserved.
authors.affiliation: Institute of Pharmacology, Siberian Division of the Russian Academy of Medical Sciences, Tomsk; Scientific Future Management Company, Novosibirsk, Russia.
authors.forename: A M
authors.initials: AM
authors.lastname: Dygai
authors.forename: E G
authors.initials: EG
authors.lastname: Skurikhin
authors.forename: N N
authors.initials: NN
authors.lastname: Ermakova
authors.forename: O V
authors.initials: OV
authors.lastname: Pershina
authors.forename: V A
authors.initials: VA
authors.lastname: Krupin
authors.forename: A M
authors.initials: AM
authors.lastname: Reztsova
authors.forename: L A
authors.initials: LA
authors.lastname: Ermolaeva
authors.forename: E S
authors.initials: ES
authors.lastname: Khmelevskaya
authors.forename: I E
authors.initials: IE
authors.lastname: Stepanova
authors.forename: A V
authors.initials: AV
authors.lastname: Artamonov
authors.forename: A A
authors.initials: AA
authors.lastname: Bekarev
authors.forename: P G
authors.initials: PG
authors.lastname: Madonov
authors.forename: D N
authors.initials: DN
authors.lastname: Kinsht
authors.forename: V E
authors.initials: VE
authors.lastname: Goldberg
authors.forename: T A
authors.initials: TA
authors.lastname: Semiglazova
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001761:Bleomycin; D002196:Capillaries / Q000187:drug effects; D003094:Collagen / Q000378:metabolism; D003238:Connective Tissue / Q000187:drug effects; D004359:Drug Therapy, Combination; D004800:Enzymes, Immobilized / Q000627:therapeutic use*; D006220:Haloperidol / Q000494:pharmacology / Q000627:therapeutic use*; D006821:Hyaluronoglucosaminidase / Q000494:pharmacology / Q000627:therapeutic use*; D007249:Inflammation / Q000188:drug therapy; D008168:Lung / Q000187:drug effects / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D011092:Polyethylene Glycols; D011650:Pulmonary Alveoli / Q000187:drug effects / Q000473:pathology; D011658:Pulmonary Fibrosis / Q000139:chemically induced / Q000188:drug therapy*; D011954:Receptors, Dopamine / Q000378:metabolism; D011985:Receptors, Serotonin / Q000378:metabolism; D020545:Respiratory Mucosa / Q000187:drug effects*
chemical_list: D014150:Antipsychotic Agents; D004800:Enzymes, Immobilized; D011954:Receptors, Dopamine; D011985:Receptors, Serotonin; D001761:Bleomycin; D011092:Polyethylene Glycols; D003094:Collagen; D006821:Hyaluronoglucosaminidase; D006220:Haloperidol